John C. Byrd

The Ohio State University — United States

Medicine · Health Sciences

116h-index63.7kcitations1.3kworks6.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(882), Lymphoma Diagnosis and Treatment(393), Acute Myeloid Leukemia Research(239), Chronic Myeloid Leukemia Treatments(174), Immunodeficiency and Autoimmune Disorders(171)

Publications1.3k total

Exploiting RAS pathway addiction as a therapeutic vulnerability in myeloid sarcoma
Blood·2025
Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor
Blood·2025
Systematic molecular profiling to identify determinants of response to ibrutinib
Blood·2025Open Access
ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases
Blood·2025Open Access
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)
Leukemia·2025· 1 citedOpen Access
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
American Journal of Hematology·2025· 1 citedOpen Access
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology·2025· 19 citedOpen Access
Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML
Blood Neoplasia·2025· 1 citedOpen Access
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
Blood·2025· 19 citedOpen Access
DHODH inhibition alters T cell metabolism limiting acute graft-versus<i>-</i>host disease while retaining <i>graft-</i>versus<i>-</i>leukemia response
The Journal of Immunology·2025Open Access
DHODH Inhibition Modulates T Cell Metabolism, Selectively Impairs Effector T Cell Response, Limiting Gvhd While Preserving GVL.
Transplantation and Cellular Therapy·2025
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Leukemia·2024Open Access
A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
Blood·2024· 4 cited
Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey
Blood·2024· 1 cited
<i>BRAF</i>-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML
Blood·2024
A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
Blood·2024
LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
Blood·2024· 7 cited
Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with <i>NPM1</i> Mutations or <i>KMT2A</i> rearrangements from the Beat AML Master Clinical Trial
Blood·2024· 2 citedOpen Access
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
Blood·2024
Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation
Blood·2024· 1 citedOpen Access
page 1 of 68Next →

Frequent Co-authors

Amy J. Johnson(18), Jennifer A. Woyach(13), Michael R. Grever(11), Thomas J. Kipps(11), Richard R. Furman(11), Jeffrey A. Jones(10), Nyla A. Heerema(10), Gerard Lozanski(9), Steven Coutré(9), Peter Hillmen(8), Susan O’Brien(8), Kristie A. Blum(8), Danelle F. James(8), Michael A. Caligiuri(7), Joseph M. Flynn(7), Clara D. Bloomfield(7), Jennifer R. Brown(6), Kami J. Maddocks(6), Jan A. Burger(6), Weiqiang Zhao(6)